Eisai and Biogen Secure NMPA Acceptance for Subcutaneous LEQEMBI in China

If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the initiation of treatment for...

January 07, 2026 | Wednesday | News
MindRank Initiates Pivotal Phase III Trial for AI-Designed Oral GLP-1 Candidate MDR-001

MDR-001 progressed from program discovery to Phase III in just 4.5 years, much faster than traditional development cycles. Phase IIb data demonstrated...

January 07, 2026 | Wednesday | News
Kelun-Biotech’s TROP2 ADC sac-TMT Combo with Keytruda Granted Breakthrough Therapy Designation in China for First-Line NSCLC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK)  announced that its TROP2-directed antibody-drug ...

January 06, 2026 | Tuesday | News
Samsung Bioepis Reclaims European Commercial Rights for BYOOVIZ®, Expanding Direct Biosimilar Portfolio

Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ® BYOOVIZ becomes the fourth biosimi...

January 05, 2026 | Monday | News
Mabwell Secures Indonesian Approval for Adalimumab Biosimilar JUNMAIKANG

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its Adalimumab Injection 9MW01...

January 02, 2026 | Friday | News
Valneva Regains Full Rights to Single-Shot Chikungunya Vaccine, Ends Licensing Deal with Serum Institute of India

Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Grou...

January 02, 2026 | Friday | News
Mabwell Doses First Patient in World’s First Phase II Trial of Anti-IL-11 Antibody for Pathological Scarring

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of...

January 01, 2026 | Thursday | News
Palisade Bio Secures Japanese Patent for Gut-Targeted PDE4 Inhibitor PALI-2108

PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon for treatment of ulcerative colitis (UC) and fibroste...

January 01, 2026 | Thursday | News
Transcenta Therapeutics Enters Strategic Bioprocessing Collaboration With EirGenix

  Transcenta Holding Limited (HKEX: 06628) (“Transcenta Therapeutics”), a global clinical stage biopharmaceutical company with fully-inte...

December 31, 2025 | Wednesday | News
HUTCHMED’s Fanregratinib NDA for Intrahepatic Cholangiocarcinoma Accepted for Priority Review in China

NDA supported by results from a Phase II registration trial in China — — Second most common form of liver cancer after hepatocellular ...

December 31, 2025 | Wednesday | News
CARsgen Submits Dual IND Applications in China for Allogeneic BCMA CAR-T CT0596 in Multiple Myeloma and Plasma Cell Leukemia

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submi...

December 30, 2025 | Tuesday | News
Harbour BioMed Forms Strategic Alliance With Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immuno...

December 30, 2025 | Tuesday | News
Viva Biotech Showcases Integrated PK/PD Platform Across Small Molecules, Peptides, PROTACs, and Antibodies

Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader and m...

December 30, 2025 | Tuesday | News
T-MAXIMUM Pharmaceutical Secures FDA IND Clearance for Allogeneic CAR-T MT027 in Recurrent Glioblastoma

T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food an...

December 29, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close